REN and metabolic dysfunction-associated steatotic liver disease: However, the efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in treating human NAFLD remains uncertain [16]; additionally, the effects of these drugs may be attenuated by the stimulation of renin resulting from the negative feedback loop because of the decreased Ang II activation [17].